Faculty of Medicine, Division of Community Health and Humanity, Clinical Epidemiology Unit, Memorial University of Newfoundland, St. John's, NL, Canada.
Faculty of Medicine, Division of Respirology, Memorial University of Newfoundland, St. John's, NL, Canada.
COPD. 2022;19(1):47-56. doi: 10.1080/15412555.2021.2024159. Epub 2022 Jan 10.
Asthma patients may have an increased risk for diagnosis of chronic obstructive pulmonary disease (COPD). However, risk factors accelerating time-to-COPD diagnosis are unclear. This study aims to estimate risk factors associated with the incidence of COPD diagnosis in asthma patients. Canada's Population Data BC (PopData BC) was used to identify asthma patients without prior COPD diagnosis between January 1, 1998, to December 31, 1999. Patients were assessed for time-to-incidence of COPD diagnosis from January 1, 2000, to December 31, 2018. The study estimated the effects of several risk factors in predicting the incidence of COPD in asthma patients during the 18-year follow-up period. Patient factors such as Medication Adherence (MA) were assessed by the proportion of days covered (PDC) and the medication possession ratio (MPR). The log-logistic mixed-effects accelerated failure time model was used to estimate the adjusted (aFTR) and 95% Confidence Interval (95% CI) for factors predicting time-to-COPD diagnosis among asthma patients. We identified 68,211 asthma patients with a mean age of 48.2 years included in the analysis. Risk factors accelerating time-to-COPD diagnosis included: male sex (aFTR: 0.62, 95% CI:0.56-0.68), older adults (age > 40 years) [aFTR: 0.03, 95% CI: 0.02-0.04], history of tobacco smoking (aFTR: 0.29, 95% CI: 0.13-0.68), asthma exacerbations (aFTR: 0.81, 95%CI: 0.70, 0.94), frequent emergency admissions (aFTR:0.21, 95% CI: 0.17-0.25), longer hospital stay (aFTR:0.07, 95% CI: 0.06-0.09), patients with increased burden of comorbidities (aFTR:0.28, 95% CI: 0.22-0.34), obese male sex (aFTR:0.38, 95% CI: 0.15-0.99), SABA overuse (aFTR: 0.61, 95% CI: 0.44-0.84), moderate (aFTR:0.23, 95% CI: 0.21-0.26), and severe asthma (aFTR:0.10, 95% CI: 0.08-0.12). After adjustment, MA ≥0.80 was significantly associated with 83% delayed time-to-COPD diagnosis [i.e. aFTR =1.83, 95%CI: 1.54-2.17 for PDC]. However, asthma severity significantly modifies the effect of MA independent of tobacco smoking history. The targeted intervention aimed to mitigate early diagnosis of COPD may prioritize enhancing medication adherence among asthma patients to prevent frequent exacerbation during follow-up.
哮喘患者可能有更高的诊断慢性阻塞性肺疾病(COPD)的风险。然而,加速 COPD 诊断时间的风险因素尚不清楚。本研究旨在评估与哮喘患者 COPD 诊断发病率相关的风险因素。利用加拿大人口数据不列颠哥伦比亚省(PopData BC),从 1998 年 1 月 1 日至 1999 年 12 月 31 日期间,确定了无先前 COPD 诊断的哮喘患者。从 2000 年 1 月 1 日至 2018 年 12 月 31 日评估患者的 COPD 诊断发病率时间。研究估计了几种风险因素对哮喘患者 18 年随访期间 COPD 发病率的影响。通过比例天数覆盖(PDC)和药物占有比(MPR)评估患者的药物依从性(MA)等患者因素。使用对数逻辑混合效应加速失效时间模型估计预测哮喘患者 COPD 诊断时间的因素的调整(aFTR)和 95%置信区间(95%CI)。我们确定了 68211 名平均年龄为 48.2 岁的哮喘患者纳入分析。加速 COPD 诊断时间的风险因素包括:男性(aFTR:0.62,95%CI:0.56-0.68),老年(>40 岁)[aFTR:0.03,95%CI:0.02-0.04],吸烟史(aFTR:0.29,95%CI:0.13-0.68),哮喘恶化(aFTR:0.81,95%CI:0.70-0.94),频繁急诊入院(aFTR:0.21,95%CI:0.17-0.25),住院时间延长(aFTR:0.07,95%CI:0.06-0.09),合并症负担增加(aFTR:0.28,95%CI:0.22-0.34),肥胖男性(aFTR:0.38,95%CI:0.15-0.99),沙丁胺醇过量使用(aFTR:0.61,95%CI:0.44-0.84),中度(aFTR:0.23,95%CI:0.21-0.26),和重度哮喘(aFTR:0.10,95%CI:0.08-0.12)。调整后,MA≥0.80 与 COPD 诊断时间延迟 83%显著相关[即 aFTR=1.83,95%CI:1.54-2.17 为 PDC]。然而,哮喘严重程度显著改变了 MA 的作用,独立于吸烟史。旨在减轻 COPD 早期诊断的靶向干预可能优先考虑提高哮喘患者的药物依从性,以防止随访期间频繁恶化。